A propensity score-matched analysis on biopsy methods: enhanced detection rates of prostate cancer with combined cognitive fusion-targeted biopsy
Asian Journal of Andrology · 2025
DOI: 10.4103/aja202515 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asian Journal of Andrology, 2025. Verfasst von Bi-Ran Ye und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Image-Guided Biopsy, Prostate. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
The choice of biopsy method is critical in diagnosing prostate cancer (PCa). This retrospective cohort study compared systematic biopsy (SB) or cognitive fusion-targeted biopsy combined with SB (CB) in detecting PCa and clinically significant prostate cancer (csPCa). Data from 2572 men who underwent either SB or CB in Fudan University Shanghai Cancer Center (Shanghai, China) between January 2019 and December 2023 were analyzed. Propensity score matching (PSM) was used to balance baseline characteristics, and detection rates were compared before and after PSM. Subgroup analyses based on prostate-specific antigen (PSA) levels and Prostate Imaging-Reporting and Data System (PI-RADS) scores were performed. Primary and secondary outcomes were the detection rates of PCa and csPCa, respectively. Of 2572 men, 1778 were included in the PSM analysis. Before PSM, CB had higher detection rates for both PCa (62.9% vs 52.4%, odds ratio [OR]: 1.54, P < 0.001) and csPCa (54.9% vs 43.3%, OR: 1.60, P < 0.001) compared to SB. After PSM, CB remained superior in detecting PCa (63.1% vs 47.9%, OR: 1.86, P < 0.001) and csPCa (55.0% vs 38.2%, OR: 1.98, P < 0.001). In patients with PSA 4–12 ng ml −1 (>4 ng ml -1 and ≤12 ng ml -1 , which is also applicable to the following text), CB detected more PCa (59.8% vs 40.7%, OR: 2.17, P < 0.001) and csPCa (48.1% vs 27.7%, OR: 2.42, P < 0.001). CB also showed superior csPCa detection in those with PI-RADS 3 lesions (32.1% vs 18.0%, OR: 2.15, P = 0.038). Overall, CB significantly improves PCa and csPCa detection, especially in patients with PSA 4–12 ng ml −1 or PI-RADS 3 lesions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
- Department of Oncology, Fudan University Shanghai Medical College, Shanghai 200032, China.
- Shanghai Genitourinary Cancer Institute, Fudan University, Shanghai 200032, China.
- Department of Operating Room, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Zitieren
APA
Ye, B. R., Wang, H., Zhang, Y. Q., Lin, G. W., Xu, H., Hong, Z., Dai, B., & Wan, F. N. (2025). A propensity score-matched analysis on biopsy methods: enhanced detection rates of prostate cancer with combined cognitive fusion-targeted biopsy. Asian Journal of Andrology. https://doi.org/10.4103/aja202515
Vancouver
Ye BR, Wang H, Zhang YQ, Lin GW, Xu H, Hong Z, et al. A propensity score-matched analysis on biopsy methods: enhanced detection rates of prostate cancer with combined cognitive fusion-targeted biopsy. Asian Journal of Andrology. 2025. doi:10.4103/aja202515
BibTeX
@article{Ye2025,
author = {Ye, Bi-Ran and Wang, Hui and Zhang, Yong-Qing and Lin, Guo-Wen and Xu, Hua and Hong, Zhe and Dai, Bo and Wan, Fang-Ning},
title = {A propensity score-matched analysis on biopsy methods: enhanced detection rates of prostate cancer with combined cognitive fusion-targeted biopsy},
journal = {Asian Journal of Andrology},
year = {2025},
doi = {10.4103/aja202515}
}
EUVIMED